Clinical Focus ›› 2016, Vol. 31 ›› Issue (2): 201-203.doi: 10.3969/j.issn.1004-583X.2016.02.016

Previous Articles     Next Articles

Clinical study of secondary prevention of aspirin in different ages of patients with cerebral infarction

Wu Xueyong, Lu Changsheng, Li Shanghua, Huang Xiong, Li Chunmei   

  1. Department of Neurology, Gaozhou People's Hospital, Gaozhuo 525200, China
  • Received:2015-10-22 Online:2016-02-05 Published:2016-04-18
  • Contact: Wu Xueyong, Email: gaw42h@163.com

Abstract: Objective To explore the secondary preventive effect of aspirin in different ages of patients with cerebral infarction.Methods A retrospective analysis was applied in all patients with cerebral infarction who were divided into five different age groups and every age group had the exposure group (aspirin treatment) and no-exposure group (control group). Recurrence of cerebral infarction, hemorrhage, subarachnoid hemorrhage and gastrointestinal bleeding were compared among groups.Results Incidence of recurrence of cerebral infarction in exposure groups were significantly lower than that of no-exposure groups (P<0.05) and no-exposure groups had significantly lower incidence of gastrointestinal bleeding (P<0.05) among different age groups. The increased incidence of cerebral and subarachnoid hemorrhage in exposure groups significantly decreased (P<0.05) compared with no-exposure groups at 61-90 ages. In exposure groups at 41-80 ages, there were no significant difference in incidence of cerebral and subarachnoid hemorrhage (P>0.05). However, the incidence of cerebral and subarachnoid hemorrhage raised significantly at 71-90 ages (P<0.05). The number of patients who needed treat ment increased significantly at 71-90 ages (P<0.05); The relative risk was highest at 61-70 ages and the attributive risk was highest at 81-90 ages.Conclusion There were differences in secondary prevention of aspirin in different ages of patients with cerebral infarction. There were maximum benefit and minimum risk to have secondary prevention of aspirin in patients with cerebral infarction at 41-60 ages.

Key words: cerebral infarction, aspirin, secondary prevention

CLC Number: